Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy. These findings, which stem from the ASCENT-03 trial in triple-negative breast cancer co-led by investigators at Dana-Farber Cancer Institute, are presented today at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. They are also published simultaneously in The New England Journal of Medicine.

October 20, 2025


October 20 2025

October 19 2025

October 18 2025

October 17 2025

October 16 2025

October 15 2025

October 14 2025

October 13 2025

October 12 2025

October 11 2025

October 10 2025

October 9 2025

October 8 2025

October 7 2025

October 6 2025